Street taps Epocrates for research

The research arm of investment banking firm Goldman Sachs will look to promote Epocrates' marketing research services. Financial terms of the three-year agreement were not disclosed.

Hudson Street, a Goldman Sachs business, will seek to connect Epocrates to buyside investors and portfolio managers for use in investigating potential pharma and biotech investments.

“We have a highly targeted panel that they can reach,” said Kirk Loevner, Epocrates chairman and chief executive officer.

Epocrates claims 500,000 active clinician users in its subscriber base. Of those, 200,000 are active US physicians, and 145,000 of those have opted into the marketing research service.

Epocrates, also known for its clinical information and decision support tools, already works with about 150 marketing research firms. They are drawn to the vendor's ability to tap into its physician panel, by specialty and by geography, and get answers to surveys. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.